Related Experiment Videos
In vitro activity of roxithromycin against Moraxella catarrhalis
1Department of Bacteriology, Royal Hallamshire Hospital, Sheffield, United Kingdom.
Diagnostic Microbiology and Infectious Disease
|May 1, 1992
Summary
Roxithromycin demonstrated potent in vitro activity against Moraxella catarrhalis, including beta-lactamase producing strains. Its effectiveness suggests it is a promising treatment for respiratory tract infections in all age groups.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Moraxella catarrhalis is a significant pathogen causing respiratory tract infections.
- Antimicrobial resistance, including beta-lactamase production, is a growing concern in treating M. catarrhalis infections.
Purpose of the Study:
- To compare the in vitro antimicrobial activity of roxithromycin with other agents against clinical isolates of Moraxella catarrhalis.
- To evaluate roxithromycin's potential as a treatment for respiratory infections caused by M. catarrhalis.
Main Methods:
- In vitro susceptibility testing was performed on 188 clinical isolates of Moraxella catarrhalis.
- Minimum Inhibitory Concentration 90 (MIC90) values were determined for roxithromycin, erythromycin, tetracycline, ampicillin, and cotrimoxazole.
Main Results:
- Roxithromycin exhibited potent activity with an MIC90 of 0.25 µg/ml.
- This was significantly lower than erythromycin (0.5 µg/ml), tetracycline (1 µg/ml), and ampicillin (>8 µg/ml).
- Roxithromycin was also effective against beta-lactamase producing strains (66% of isolates).
Conclusions:
- Roxithromycin shows superior in vitro activity against Moraxella catarrhalis compared to other tested antibiotics.
- Its favorable pharmacokinetic profile and potent activity suggest roxithromycin is a viable therapeutic option for respiratory tract infections in both children and adults.